{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T10:56:17Z","timestamp":1764413777918,"version":"3.40.5"},"reference-count":37,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cytometry Part B Clinical"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Minimal residual disease (MRD) assessment of hematopoietic neoplasia below 10<jats:sup>\u22124<\/jats:sup> requires more leukocytes than is usually attainable by post\u2010lysis preparation. However, not all laboratories are resourced for consensus Euroflow pre\u2010lysis methodology. Our study aim was to validate a modified pre\u2010lysis protocol against our standard post\u2010lysis method for MRD detection of multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and B\u2010non Hodgkin lymphoma (B\u2010NHL), to meet demand for deeper MRD assessment by flow cytometry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Clinical samples for MRD assessment of MM, CLL, and B\u2010NHL (50, 30, and 30 cases, respectively) were prepared in parallel by pre and post\u2010lysis methods for the initial validation. Total leukocytes, MRD, and median fluorescence intensity of antigen expression were compared as measures of sensitivity and antigen stability. Lymphocyte and granulocyte composition were compared, assessing relative sample processing stability. Sensitivity of the pre\u2010lysis assay was monitored post validation for a further 18\u2009months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Pre\u2010lysis achieved at least 10<jats:sup>\u22124<\/jats:sup> sensitivity in 85% MM, 81% CLL, and 90% B\u2010NHL samples versus 24%, 48%, and 26% by post\u2010lysis, respectively, with stable antigen expression and leukocyte composition. Post validation over 18\u2009months with technical expertise improving, pre\u2010lysis permitted 10<jats:sup>\u22125<\/jats:sup> MRD assessment in 69%, 86%, and 82% of the respective patient groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This modified pre\u2010lysis procedure provides a sensitive, robust, time efficient, and relatively cost\u2010effective alternative for MRD testing by MFC at 10<jats:sup>\u22125<\/jats:sup>, facilitating clinically meaningful deeper response assessment for MM, CLL, and B\u2010NHL. This method adaptation may facilitate more widespread adoption of highly sensitive flow cytometry\u2010based MRD assessment.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cyto.b.21893","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T14:44:40Z","timestamp":1591973080000},"page":"385-398","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Validation of a modified pre\u2010lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B\u2010non Hodgkin lymphoma"],"prefix":"10.1002","volume":"98","author":[{"given":"Emma","family":"Bayly","sequence":"first","affiliation":[{"name":"Pathology Department Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Clinical Haematology Victorian Comprehensive Cancer Centre  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vuong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Pathology Department Peter MacCallum Cancer Centre  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Binek","sequence":"additional","affiliation":[{"name":"Pathology Department Peter MacCallum Cancer Centre  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Piggin","sequence":"additional","affiliation":[{"name":"Pathology Department Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Clinical Haematology Victorian Comprehensive Cancer Centre  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kylie","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Pathology Department Peter MacCallum Cancer Centre  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Westerman","sequence":"additional","affiliation":[{"name":"Pathology Department Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Clinical Haematology Victorian Comprehensive Cancer Centre  Melbourne Victoria Australia"},{"name":"Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre The University of Melbourne  Parkville Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4715-3886","authenticated-orcid":false,"given":"Neil","family":"Came","sequence":"additional","affiliation":[{"name":"Pathology Department Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre The University of Melbourne  Parkville Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21228"},{"key":"e_1_2_7_3_1","first-page":"103","article-title":"Optimization and validation of an 8\u2010color single\u2010tube assay for the sensitive detection of minimal residual disease in B\u2010cell chronic lymphocytic leukemia detected via flow cytometry","volume":"47","author":"Dowling A. K.","year":"2016","journal-title":"Laboratoriums Medizin"},{"key":"e_1_2_7_4_1","unstructured":"EuroFlow. EuroFlow Standard Operating Procedure (SOP) for Bulk Lysis for MRD panels. Version 1.3 (June 25 2018);https:\/\/euroflow.org\/usr\/pub\/protocols.php."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-506170"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12757"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21609"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.90"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12789"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.122"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0320(19981215)34:6<264::AID-CYTO4>3.0.CO;2-P"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12755"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/cyto.b.21194","article-title":"Flow cytometric analysis of chronic lymphocytic leukaemia minimal residual disease (CLLMRD) using conventional gating versus radar plot (Kaluza\u00ae Beckman coulter, Inc). Abstracts for ESCCA 2014 conference: Exploring new Frontiers in flow cytometry September 14\u201317, 2014, Lisbon, Portugal","volume":"86","author":"Nguyen V.","year":"2014","journal-title":"Cytometry. Part B, Clinical Cytometry"},{"key":"e_1_2_7_16_1","first-page":"335","article-title":"Application of eight\u2010colour flow cytometry (FC) in the assessment of plasma cell myeloma (PCM) at Peter MacCallum Cancer Centre (PMCC). Abstracts from the 27th annual meeting of the international clinical cytometry society, New Orleans, October 5\u20139, 2012","volume":"82","author":"Nguyen V.","year":"2012","journal-title":"Cytometry. Part B, Clinical Cytometry"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.4110\/in.2013.13.2.43"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21276"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01231"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-568907"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-159624"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.216"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.313"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11080"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21272"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404584"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2018.02.011"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqw052"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-801498"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21862"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21249"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21106"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-726307"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.005801"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21239"},{"key":"e_1_2_7_38_1","unstructured":"Cytometry. Part B Clinical Cytometry 2006 72 Suppl 1 Bethesda international consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia"}],"container-title":["Cytometry Part B: Clinical Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcyto.b.21893","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.21893","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cyto.b.21893","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.21893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T20:48:36Z","timestamp":1693946916000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cyto.b.21893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1002\/cyto.b.21893"],"URL":"https:\/\/doi.org\/10.1002\/cyto.b.21893","archive":["Portico"],"relation":{},"ISSN":["1552-4949","1552-4957"],"issn-type":[{"type":"print","value":"1552-4949"},{"type":"electronic","value":"1552-4957"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"2019-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}